Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report) dropped 8.3% during trading on Wednesday . The stock traded as low as $11.55 and last traded at $11.9580. Approximately 163,800 shares traded hands during trading, a decline of 93% from the average daily volume of 2,440,812 shares. The stock had previously closed at $13.04.
NovaBay Pharmaceuticals Trading Down 11.3%
The company has a market cap of $1.46 billion, a price-to-earnings ratio of -1.16 and a beta of 0.09. The stock’s 50-day moving average is $3.71 and its 200-day moving average is $2.12.
Institutional Investors Weigh In On NovaBay Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in NBY. C2C Wealth Management LLC raised its position in shares of NovaBay Pharmaceuticals by 78.2% during the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 43,000 shares during the period. Apollon Wealth Management LLC acquired a new stake in NovaBay Pharmaceuticals in the 3rd quarter valued at $35,000. Finally, Ground Swell Capital LLC acquired a new stake in NovaBay Pharmaceuticals in the 3rd quarter valued at $25,000. Institutional investors and hedge funds own 23.25% of the company’s stock.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.
The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- Punch these codes into your ordinary brokerage account
- A U.S. “birthright” claim worth trillions – activated quietly
- Melt-up warning
- More than 2 million ounces defined – and still early in their story
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
